Literature DB >> 20689445

Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Chandra M V Goparaju1, Harvey I Pass, Justin D Blasberg, Nathalie Hirsch, Jessica S Donington.   

Abstract

INTRODUCTION: Osteopontin (OPN) is a multifunctional protein with an important but poorly understood role in non-small cell lung cancer (NSCLC) pathogenesis. Moreover, the role of the three known mRNA isoforms (OPNa, OPNb, and OPNc) has not been reported. We hypothesize that OPN isoforms play different roles in determining the metastatic potential of NSCLC.
METHODS: We amplified mRNA for each OPN isoform in NSCLC tumors and matched normal lung. The functional impact of each isoform was evaluated by transfecting cDNA plasmids specific to each isoform into NSCLC cell lines and comparing behavior to empty vector controls in scratch closure, cell proliferation, soft-agar colony formation, and Matrigel invasion assays. Gene array was used to evaluate differences in downstream targets and was compared with a panel of markers for epithelial-mesenchymal transition (EMT).
RESULTS: OPNa expression was increased in 91% of NSCLC tumors compared with matched lung. OPNa overexpression significantly increased activity in scratch closure, proliferation, soft-agar colony formation, and Matrigel invasion assays compared with controls in all cell lines. OPNb overexpression produced a less significant modulation of function. OPNc overexpression significantly decreased activity in proliferation, colony formation, and invasion assays compared with controls. Expression arrays revealed an increase in EMT with OPNa overexpression but not OPNc. Differences were validated by quantitative reverse transcriptase-polymerase chain reaction.
CONCLUSIONS: Overexpression of the individual OPN isoforms in NSCLC results in divergent functional phenotypes. OPNa produced an aggressive phenotype, whereas OPNc produced a more indolent phenotype. Exon 4, which is transcribed in OPNa but absent in OPNc, may be central to this phenomenon and could serve as a target for isoform-specific inhibition of OPN in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689445      PMCID: PMC3122268          DOI: 10.1097/JTO.0b013e3181eba6bd

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  24 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Summaries of Affymetrix GeneChip probe level data.

Authors:  Rafael A Irizarry; Benjamin M Bolstad; Francois Collin; Leslie M Cope; Bridget Hobbs; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

3.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

4.  Differential osteopontin expression in lung cancer.

Authors:  J Zhang; K Takahashi; F Takahashi; K Shimizu; F Ohshita; Y Kameda; K Maeda; K Nishio; Y Fukuchi
Journal:  Cancer Lett       Date:  2001-10-10       Impact factor: 8.679

5.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.

Authors:  H A Gardner; B Berse; D R Senger
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

6.  Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.

Authors:  E I Behrend; A M Craig; S M Wilson; D T Denhardt; A F Chambers
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.

Authors:  Justin D Blasberg; Chandra M Goparaju; Harvey I Pass; Jessica S Donington
Journal:  J Thorac Cardiovasc Surg       Date:  2009-10-09       Impact factor: 5.209

Review 8.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

9.  cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN).

Authors:  M F Young; J M Kerr; J D Termine; U M Wewer; M G Wang; O W McBride; L W Fisher
Journal:  Genomics       Date:  1990-08       Impact factor: 5.736

Review 10.  Axis of evil: molecular mechanisms of cancer metastasis.

Authors:  Thomas Bogenrieder; Meenhard Herlyn
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

View more
  22 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma.

Authors:  Nermeen S Youssef; Wesam M Osman
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.

Authors:  Bai Zhao; Tiemin Sun; Fanjuan Meng; Aibing Qu; Chunling Li; Hui Shen; Yu Jin; Wenxin Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

4.  Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.

Authors:  Syamal D Bhattacharya; Zhiyong Mi; Victoria M Kim; Hongtao Guo; Lindsay J Talbot; Paul C Kuo
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

5.  Influence of osteopontin silencing on survival and migration of lung cancer cells.

Authors:  B Polat; G Wohlleben; A Katzer; C S Djuzenova; A Technau; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

6.  Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis.

Authors:  Xue-Lin Zou; Chun Wang; K E Liu; Wen Nie; Zhen-Yu Ding
Journal:  Mol Clin Oncol       Date:  2015-02-26

Review 7.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

8.  Tumor: Stroma Interaction and Cancer.

Authors:  Michael P Rogers; Zhiyong Mi; Neill Y Li; Philip Y Wai; Paul C Kuo
Journal:  Exp Suppl       Date:  2022

Review 9.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

10.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.